Medication info
Polmin M-Extended Release Tablets 12.5/1000 mg (Empagliflozin, Metformin)

Polmin M-Extended Release Tablets 12.5/1000 mg (Empagliflozin, Metformin)

Prescription medicationTabletOral
Ingredient · strength
Empagliflozin›12.5mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
Green Cross Corp.
Appearance
Brown, biconvex, oval-shaped extended-release film-coated tablet
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 202501713 · Approved 2025.07.09 · Insurance code 643606890

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: empagliflozin 25mg and metformin hydrochloride extended-release 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, take this medicine once daily in the evening with a meal. To reduce gastrointestinal adverse effects associated with metformin use, the dose of metformin hydrochloride should be increased gradually. Take one tablet of this medicine 10/1000 mg extended-release tablet or 25/1000 mg extended-release tablet once daily. Patients taking this medicine 5/1000 mg extended-release tablet or 12.5/1000 mg extended-release tablet should take 2 tablets together once daily. For patients who are unable to achieve adequate glycemic control with metformin alone or in combination with other medicines such as insulin, the initial recommended total daily dose when taking this medicine is empagliflozin 10 mg plus the patient's existing dose of metformin. If the patient tolerates empagliflozin 10 mg well but additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg. Patients switching from combination therapy with empagliflozin and metformin to this medicine should receive the same doses of empagliflozin and metformin they were previously taking. When this medicine is coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia. Because dosage adjustment based on renal function is necessary, assessment of renal function is recommended before and periodically during treatment with this medicine. No dosage adjustment of this medicine is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60 mL/min or estimated glomerular filtration rate (eGFR) ≧ 60 mL/min/1.73 m2]. In patients with moderate renal impairment [CKD stage 3A, creatinine clearance (CrCl) ≧ 45 mL/min and <60mL/min or estimated glomerular filtration rate (eGFR) ≧ 45 mL/min/1.73m2 and <60 mL/min/1.73m2] who tolerate treatment well and do not have other symptoms that may increase the risk of lactic acidosis, this medicine may be used with adjustment of the metformin hydrochloride dose as follows. - Since the starting dose of extended-release metformin hydrochloride is 500 mg or 750 mg once daily, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000 mg. If creatinine clearance (CrCl) decreases to less than 45 ml/min or estimated glomerular filtration rate (eGFR) decreases to less than 45 ml/min/1.73m2, this medicine should be discontinued immediately. In patients 75 years of age or older, renal function and the risk of volume depletion should be considered.

Ingredients

Manufacturer
Green Cross Corp.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes mellitus

  • Abnormal blood sugar control
  • type 2 diabetes
  • cardiovascular diseases
  • cardiovascular events
View approved original text

This medication is used as an adjunct to diet and exercise to improve blood sugar control in adult patients with type 2 diabetes. It is particularly effective in patients whose blood sugar is not adequately controlled, and should be used with caution under specialist guidance in cases of existing cardiovascular diseases. Therefore, this medication helps in the management of blood sugar and in the reduction of cardiovascular risks in patients with type 2 diabetes.

How to take

Adult dose

For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: empagliflozin 25mg and metformin hydrochloride extended-release 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, take this medicine once daily in the evening with a meal. To reduce gastrointestinal adverse effects associated with metformin use, the dose of metformin hydrochloride should be increased gradually. Take one tablet of this medicine 10/1000 mg extended-release tablet or 25/1000 mg extended-release tablet once daily. Patients taking this medicine 5/1000 mg extended-release tablet or 12.5/1000 mg extended-release tablet should take 2 tablets together once daily. For patients who are unable to achieve adequate glycemic control with metformin alone or in combination with other medicines such as insulin, the initial recommended total daily dose when taking this medicine is empagliflozin 10 mg plus the patient's existing dose of metformin. If the patient tolerates empagliflozin 10 mg well but additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg. Patients switching from combination therapy with empagliflozin and metformin to this medicine should receive the same doses of empagliflozin and metformin they were previously taking. When this medicine is coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia. Because dosage adjustment based on renal function is necessary, assessment of renal function is recommended before and periodically during treatment with this medicine. No dosage adjustment of this medicine is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60 mL/min or estimated glomerular filtration rate (eGFR) ≧ 60 mL/min/1.73 m2]. In patients with moderate renal impairment [CKD stage 3A, creatinine clearance (CrCl) ≧ 45 mL/min and <60mL/min or estimated glomerular filtration rate (eGFR) ≧ 45 mL/min/1.73m2 and <60 mL/min/1.73m2] who tolerate treatment well and do not have other symptoms that may increase the risk of lactic acidosis, this medicine may be used with adjustment of the metformin hydrochloride dose as follows. - Since the starting dose of extended-release metformin hydrochloride is 500 mg or 750 mg once daily, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000 mg. If creatinine clearance (CrCl) decreases to less than 45 ml/min or estimated glomerular filtration rate (eGFR) decreases to less than 45 ml/min/1.73m2, this medicine should be discontinued immediately. In patients 75 years of age or older, renal function and the risk of volume depletion should be considered.

Precautions

This medication contains two components for treating diabetes. Caution is required since rare side effects, such as severe lactic acidosis, may occur while taking this medication. Lactic acidosis is a serious condition resulting from an excessive buildup of lactic acid in the body and can sometimes be life-threatening. Moreover, the risk of hypoglycemia may increase when this medication is taken in conjunction with insulin or sulfonylureas, so blood sugar levels should be closely monitored. Patients with significantly impaired kidney function or certain severe illnesses should not take this medication. As this medication can affect kidney function, regular kidney function tests should be conducted before and during treatment. In special circumstances, such as dehydration, severe infections, unstable heart function, or before and after surgeries, temporarily discontinuing the medication may be necessary. There may be an increased risk of genital and urinary tract infections, so if symptoms of infection occur, immediate consultation with a healthcare provider is advised. Additionally, vitamin B12 deficiency may occur, thus checking through blood tests during long-term use is recommended. It is safest for pregnant women, women who may become pregnant, and breastfeeding women to avoid this medication. Caution is also advised for elderly patients, those with poor nutritional status, and those who consume alcohol excessively. This medication may interact with other drugs, so it is essential to inform healthcare providers of any other medications being taken, especially when taken with drugs that may affect kidney function. Tablets should be swallowed whole, and while the coating may be excreted in stool, this is normal. If abnormal symptoms occur, consult a doctor immediately and regular check-ups are necessary to ensure safe medication use.

Side effects

Severe lactic acidosis, severe hypoglycemia, hypoglycemia, urinary tract infection, genital infection, increased urination, reduced and deficient vitamin B12, ketoacidosis, lactic acidosis, decreased fluid volume, nausea, vomiting, diarrhea, abdominal pain, loss of appetite, constipation, abnormal liver function tests, hepatitis, altered taste, itching, rash, urticaria, erythema, angioedema, dysuria, interstitial nephritis, thirst, increased serum lipids, elevated blood creatinine, reduced glomerular filtration rate, vulvovaginal yeast infection, vulvitis, balanitis, perineal necrosis, elevated blood creatinine, reduced glomerular filtration rate, gastrointestinal symptoms (diarrhea, nausea, vomiting), ketoacidosis, urosepsis, pyelonephritis, rash, urticaria, angioedema, perineal necrosis, chronic gastritis, cerebral infarction, soft tissue infection, pneumonia, ankle fracture, epicondylitis, facial bone fracture, musculoskeletal pain, myocardial infarction, pancreatic adenocarcinoma, constipation, gastritis, abdominal discomfort, anal incontinence, dry mouth, gastrointestinal disorder, oral discomfort, salivary gland pain, headache, dizziness, asthenia, chest discomfort, chest pain, nasopharyngitis, upper respiratory infection, insomnia, anxiety, depression, sleep disorders, ear pain, orthostatic dizziness, dizziness, anemia, lymphadenopathy, hypothyroidism, thyroid nodule, diabetic foot, dermoid cyst, seborrheic dermatitis, atopic dermatitis, nummular eczema, heat rash, sebaceous gland hyperplasia, lumbar spinal canal stenosis, myalgia, limb pain, musculoskeletal chest pain, arthralgia, cervical stenosis, fibromyalgia, flank pain, fracture pain, muscle weakness, osteoarthritis, osteoporosis, rotator cuff syndrome, astigmatism, cataract, allergic conjunctivitis, blurred vision, corneal abrasion, glaucoma, macular fibrosis, ocular discomfort, conjunctival injection, pathological myopia, retinal detachment, retinal floaters, retinal vein occlusion, traction retinal detachment, eyelid swelling, visual impairment, vitreous floaters, vitreous hemorrhage, epistaxis, asthma, age-related dyspnea, wet cough, allergic rhinitis, residual phlegm, skin laceration, contusion, rib fracture, concussion, corneal abrasion, fall, hand fracture, iliotibial band syndrome, open globe injury, pelvic fracture, road traffic accident, splenic injury, sternum fracture, angina pectoris, palpitations, Prinzmetal angina, coronary artery disease, tachycardia, atherosclerosis, deep vein thrombosis, diabetic vascular disorders, peripheral artery occlusive disease, benign neoplasm of the ampulla of Vater, benign ovarian tumor, bladder cancer, cholesteatoma, gastric cancer, leiomyoma, pancreatic adenocarcinoma, rectal cancer, thyroid cancer, uterine leiomyoma, anxiety, acute cholecystitis, autoimmune hepatitis, cholelithiasis, hepatitis, ear pain, orthostatic dizziness, dizziness, anemia, lymphadenopathy, hypothyroidism, thyroid nodule

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air and moisture, so it should be stored in a tightly sealed container. It is important to maintain storage temperatures between 1 degrees and 30 degrees Celsius to preserve the medication's efficacy and safety.

Appearance and packaging

Appearance

Brown, biconvex, oval-shaped extended-release film-coated tablet

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.